Scholarlink

Background <p>Berberine (BBR) is an alkaloid derived from traditional Chinese herbal remedies, like Huanglian and Huangbai. It possesses a range of anti-inflammatory properties but is known to cause significant irritation upon injection and has a poor taste when consumed orally, with limited absorption into the body. Berberine microcapsules (BBR-M) were developed using solid dispersion (SD) and microcapsule technology for a <i>Salmonella enteritidis-</i>infected mouse enteritis model experiment to test their efficacy in regulating <i>Salmonella enteritidis</i> by analyzing RT- qPCR testing results, alongside 16&#xa0;S rDNA sequencing data and immunohistochemistry analysis to determine the dosage and mechanism of action of BBR-M.</p> Results <p>The results demonstrated that BBR-M exhibited good intestinal sustained-release characteristics and storage stability. Each dose of BBR-M could alleviate intestinal injury, modulating immunoglobulin profiles and differentially regulating pro-inflammatory (IL-6, IL-1β, TNF-α) and anti-inflammatory (IL-10) cytokine expression; particularly at the 40&#xa0;mg/kg dosage, it significantly restored microbial homeostasis through selective reduction of enteropathogens (<i>Escherichia coli</i>, <i>Shigella</i>, <i>Klebsiella</i>, <i>Salmonella</i>) and enrichment of commensal probiotics (<i>Akkermansia muciniphila</i>).</p> Conclusions <p>Collectively, these findings position the medium-dose BBR-M regimen as a promising therapeutic candidate for <i>Salmonella enteritidis</i> enteritis intervention, demonstrating optimal efficacy in pathogen clearance, inflammatory modulation, and intestinal barrier restoration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the therapeutic effect of Berberine microcapsules on Salmonella enteritidis-infected mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月6日

查看全文
  • Li Yang,
  • Yanjie Qiao,
  • Rulong Chen,
  • Mengmeng Wang,
  • Bao Zhou,
  • Xumei Zhang,
  • Yan Zhao,
  • Huijun Shi,
  • Lining Xia,
  • Qiang Fu

摘要

Background

Berberine (BBR) is an alkaloid derived from traditional Chinese herbal remedies, like Huanglian and Huangbai. It possesses a range of anti-inflammatory properties but is known to cause significant irritation upon injection and has a poor taste when consumed orally, with limited absorption into the body. Berberine microcapsules (BBR-M) were developed using solid dispersion (SD) and microcapsule technology for a Salmonella enteritidis-infected mouse enteritis model experiment to test their efficacy in regulating Salmonella enteritidis by analyzing RT- qPCR testing results, alongside 16 S rDNA sequencing data and immunohistochemistry analysis to determine the dosage and mechanism of action of BBR-M.

Results

The results demonstrated that BBR-M exhibited good intestinal sustained-release characteristics and storage stability. Each dose of BBR-M could alleviate intestinal injury, modulating immunoglobulin profiles and differentially regulating pro-inflammatory (IL-6, IL-1β, TNF-α) and anti-inflammatory (IL-10) cytokine expression; particularly at the 40 mg/kg dosage, it significantly restored microbial homeostasis through selective reduction of enteropathogens (Escherichia coli, Shigella, Klebsiella, Salmonella) and enrichment of commensal probiotics (Akkermansia muciniphila).

Conclusions

Collectively, these findings position the medium-dose BBR-M regimen as a promising therapeutic candidate for Salmonella enteritidis enteritis intervention, demonstrating optimal efficacy in pathogen clearance, inflammatory modulation, and intestinal barrier restoration.